For a patient, the value of a therapy can mean living a normal life, even for part of the day. For a payer, value can mean improvement in health for a reasonable amount of money. For a manufacturer, it can mean broad access to the given patient population that will respond positively to a drug. And then there’s the growing role of Health Technology Assessments in seeking to create a standardized, data-driven, and evidence-based approach to measuring the value of a drug. How can we meet in the middle?